SEC Form 4 · accession 0001179110-17-009188
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laurie Stelzer
Officer — SVP, Chief Financial Officer
Period of report
Jun 15, 2017
Accepted (ET)
Jun 16, 2017 · 4:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2017 | M | 6,875 | $0.00 | A | 27,785 | D | |
| Common StockF1 | Jun 15, 2017 | F | 2,583 | $13.05 | D | 25,202 | D | |
| Common StockF2 | holding | — | — | — | 10,000 | I | By trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3 | $0.00 | Jun 15, 2017 | M | 6,875 | D | — | — | Common Stock | 6,875 | 13,750 | D |
Explanation of responses
- F1The reported disposition of 2,583 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations.
- F2The reporting person is co-trustee of the Gregory and Laureen Stelzer Living Trust.
- F3This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.